A new study demonstrated that measuring anti-acetylcholine receptor antibody (AChR) levels over time may help predict the worsening of myasthenia gravis (MG) in patients who have reached minimal symptom expression (MSE). MSE occurs when a patient’s symptoms are well-managed, with little to no impact on daily living.
The research, published in Frontiers in Immunology, analyzed data from two groups: a primary group of 339 patients and a second group of 60 patients, used to confirm the findings. The main group consisted of approximately 63% women and 37% men, and researchers monitored their clinical status for an average of nearly six years. All participants were patients with MG who had reached the MSE stage.
To evaluate disease stability, scientists used the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, which measures the extent to which the disease affects activities such as breathing, talking and eating. A score of 0 or 1 on this scale indicates that a patient has reached the stable state (MSE); a worsening was defined as an increase of two or more points on the MG-ADL scale.
The study revealed a strong correlation between AChR antibody levels and a patient’s clinical state. These levels are typically moderate at disease onset but climb to their highest point during the stage of peak symptom severity. Once a patient reaches the MSE stage, AChR antibody levels drop significantly.
By using this stable phase as a personal baseline, the study found that any subsequent spike in AChR-ab levels was a strong indicator of a coming relapse.
In contrast, patients who remained in the MSE stage showed AChR antibody levels that were even lower than when they first achieved stability. This direct link between antibody fluctuations and physical health was confirmed across multiple clinical tests, proving that monitoring these levels can accurately reflect changes in a patient’s daily functioning.
Learn more about MG causes and risk factors
The researchers identified several other clinical factors that contribute to the risk of future worsening. Patients faced a higher risk of relapse if they had a shorter disease duration before reaching stability, a history of myasthenic crises or comorbid immune-related diseases.
Additionally, the presence of a thymoma, a tumor of the thymus gland, served as a predictor of future instability.
The median time to a relapse after achieving stability was 35.1 months. While many patients remained stable for years, 25% experienced worsening within the first year (12.7 months) after reaching MSE.
“These findings confirm that longitudinal AChR-ab levels may serve as reliable biomarkers for tracking disease progression and predicting exacerbation risk in MG,” the authors concluded. However, they noted that, to confirm these results and develop highly accurate clinical prediction tools, subsequent research should incorporate broader participant groups and more detailed classifications of antibody subtypes.
Sign up here to get the latest news, perspectives, and information about MG sent directly to your inbox. Registration is free and only takes a minute.
